Cisplatin-Induced Hearing Loss (CIHL) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Description
Cisplatin-Induced Hearing Loss (CIHL) Market Outlook
Thelansis’s “Cisplatin-Induced Hearing Loss (CIHL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cisplatin-Induced Hearing Loss treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Cisplatin-Induced Hearing Loss (CIHL) Overview
Cisplatin-induced hearing loss (CIHL) is a highly prevalent, progressive, and typically irreversible bilateral sensorineural hearing impairment, representing a major dose-limiting toxicity of platinum-based chemotherapy. The condition arises due to the accumulation and prolonged retention of cisplatin within the cochlea, where it generates excessive reactive oxygen species (ROS), leading to oxidative stress and apoptosis of critical auditory structures, including outer hair cells, spiral ganglion neurons, and the stria vascularis.
Clinically, CIHL initially presents with tinnitus and high-frequency hearing loss (4,000–8,000 Hz), which progressively extends into speech frequencies, resulting in significant communication impairment. The impact is particularly severe in pediatric populations, where it can lead to speech, developmental, and neurocognitive delays, while in adults it contributes to substantial quality-of-life deterioration.
Management requires rigorous audiological monitoring, including extended high-frequency audiometry and otoacoustic emissions (OAEs), conducted at baseline and throughout chemotherapy. Historically, preventive strategies were limited due to concerns of compromising anticancer efficacy. However, recent advances have introduced intravenous sodium thiosulfate (STS) as the first approved protective agent in pediatric patients, administered post-cisplatin infusion to mitigate ototoxicity while preserving tumor response, marking a significant advancement in survivorship care.
Key Highlights
CIHL is a common, irreversible chemotherapy toxicity with significant long-term impact
US incidence expected to increase from ~378K to ~398K (~0.5% CAGR)
Market Overview
Germany market projected to grow from ~$0.7M to ~$1.1M (~4–5% CAGR)
Market remains small and niche, with growth driven by protective therapies like STS and survivorship care focus
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
In-depth interviews with leading KOLs and payers
Physician surveys
RWE analysis for claims and EHR datasets
Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
What is the 10-year market outlook for sales and patient share?
Which events will have the greatest impact on the market’s trajectory?
What insights do interviewed experts provide on current and emerging treatments?
Which pipeline products show the most promise, and what is their potential for launch and future positioning?
What are the key unmet needs and KOL expectations for target profiles?
What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
and more…
Country covered:G8 Markets
United States
EU5
France
Germany
Italy
Spain
U.K.
Japan
China
Thelansis’s “Cisplatin-Induced Hearing Loss (CIHL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cisplatin-Induced Hearing Loss treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Cisplatin-Induced Hearing Loss (CIHL) Overview
Cisplatin-induced hearing loss (CIHL) is a highly prevalent, progressive, and typically irreversible bilateral sensorineural hearing impairment, representing a major dose-limiting toxicity of platinum-based chemotherapy. The condition arises due to the accumulation and prolonged retention of cisplatin within the cochlea, where it generates excessive reactive oxygen species (ROS), leading to oxidative stress and apoptosis of critical auditory structures, including outer hair cells, spiral ganglion neurons, and the stria vascularis.
Clinically, CIHL initially presents with tinnitus and high-frequency hearing loss (4,000–8,000 Hz), which progressively extends into speech frequencies, resulting in significant communication impairment. The impact is particularly severe in pediatric populations, where it can lead to speech, developmental, and neurocognitive delays, while in adults it contributes to substantial quality-of-life deterioration.
Management requires rigorous audiological monitoring, including extended high-frequency audiometry and otoacoustic emissions (OAEs), conducted at baseline and throughout chemotherapy. Historically, preventive strategies were limited due to concerns of compromising anticancer efficacy. However, recent advances have introduced intravenous sodium thiosulfate (STS) as the first approved protective agent in pediatric patients, administered post-cisplatin infusion to mitigate ototoxicity while preserving tumor response, marking a significant advancement in survivorship care.
Key Highlights
CIHL is a common, irreversible chemotherapy toxicity with significant long-term impact
US incidence expected to increase from ~378K to ~398K (~0.5% CAGR)
Market Overview
Germany market projected to grow from ~$0.7M to ~$1.1M (~4–5% CAGR)
Market remains small and niche, with growth driven by protective therapies like STS and survivorship care focus
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
In-depth interviews with leading KOLs and payers
Physician surveys
RWE analysis for claims and EHR datasets
Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
What is the 10-year market outlook for sales and patient share?
Which events will have the greatest impact on the market’s trajectory?
What insights do interviewed experts provide on current and emerging treatments?
Which pipeline products show the most promise, and what is their potential for launch and future positioning?
What are the key unmet needs and KOL expectations for target profiles?
What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
and more…
Country covered:G8 Markets
United States
EU5
France
Germany
Italy
Spain
U.K.
Japan
China
Table of Contents
154 Pages
- 1. Key Findings and Analyst Commentary
- 1.1 Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.
- 2. Disease Context
- 2.1 Disease definition, classification, etiology and pathophysiology, drug targets, etc.
- 3. Epidemiology
- 3.1 Key takeaways
- 3.2 Incidence / Prevalence
- 3.3 Diagnosed and Drug-Treated populations
- 3.4 Comorbidities
- 3.5 Other relevant patient segments
- 4. Market Size and Forecast
- 4.5 Key takeaways
- 4.6 Market drivers and constraints
- 4.7 Drug-class specific trends
- 4.8 Country-specific trends
- 5. Competitive Landscape
- 5.1 Current therapies
- 5.1.1 Key takeaways
- 5.1.2 Dx and Tx journey/algorithm
- 5.1.3 Key current therapies – profiles and KOL insights
- 5.2 Emerging therapies
- 5.2.1 Key takeaways
- 5.2.2 Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- 5.2.3 Notable early-phase pipeline
- 6. Unmet Need and TPP Analysis
- 6.1 Top unmet needs and future attainment by emerging therapies
- 6.2 TPP analysis and KOL expectations
- 7. Regulatory and Reimbursement Environments (by country and payer insights)
- 8. Appendix (e.g., bibliography, methodology)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
